



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

TBOYCE@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3043


TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

JUN 25 2002

RECEIVED

TECH CENTER 1600/2900

June 6, 2002

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
June 6, 2002	
Date	Thomas M. Boyce

Commissioner for Patents
Washington, DC 20231

Re: *U.S. Patent Application No. 10/044,650 entitled "METHODS AND COMPOSITIONS FOR DELIVERY AND RETENTION OF ACTIVE AGENTS TO LYMPH NODES" by Beth A. Goins and William T. Phillips*
Client Reference: 1998-18-US1
Our Reference: UTSK:343US


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (A1-A12, C1-C90).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10200210/TMB.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,



Thomas M. Boyce
Reg. No. 43,508

TMB/cmb
Encl.: as noted

25170544.1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Beth A. Goins
William T. Phillips

Serial No.: 10/044,650

Filed: January 11, 2002


For: METHODS AND COMPOSITIONS FOR
DELIVERY AND RETENTION OF
ACTIVE AGENTS TO LYMPH NODES

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: UTSK:343US

RECEIVED
PATENT
JUN 25 2002
TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
June 6, 2002	
Date	Thomas M. Boyce

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10200210/TMB.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Thomas M. Boyce
Reg. No. 43,508
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: June 6, 2002

Form PTO-1449 (modified)

Atty. Docket No.
UTSK:343USSerial No.
10/044,650

List of Patents and Publications for Applicant's

Applicant

Beth A. Goins

William T. Phillips

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

January 11, 2002

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	4,310,505	1/12/82	Baldeschwieler <i>et al.</i>	424	1	11/8/79
	A2	4,789,736	12/6/88	Canning <i>et al.</i>	534	14	3/11/86
	A3	4,863,713	9/5/89	Goodwin <i>et al.</i>	424	1.1	6/23/86
	A4	4,904,479	2/27/90	Illum	424	490	1/15/87
	A5	5,120,526	6/9/92	Fritzberg <i>et al.</i>	424	1.1	2/4/91
	A6	5,482,698	1/9/96	Griffiths	424	141	4/22/93
	A7	5,690,907	11/25/97	Lanza <i>et al.</i>	424	9.5	6/8/95
	A8	5,698,405	12/16/97	Goldenberg	435	7.5	6/1/95
	A9	5,716,594	2/10/98	Elmaleh <i>et al.</i>	424	1.41	10/2/96
	A10	5,736,119	4/7/98	Goldenberg <i>et al.</i>	424	1.53	3/23/95
	A11	5,776,094	7/7/98	Goldenberg	604	20	6/1/95
	A12	5,792,475	8/11/98	Davis <i>et al.</i>	424	489	7/28/93

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Alving, "Liposomes as carriers of antigens and adjuvants," <i>J. Immuno Methods</i> , 140:1-13, 1991.
	C2	Barth <i>et al.</i> , "Boron neutron capture therapy of cancer," <i>Cancer Res.</i> , 50:1061-1070, 1990.

25135737.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

RECEIVED
JUN 25 2002
FBI CENTER 1600/2900

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSK:343US

10/044,650

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Beth A. Goins

William T. Phillips

Filing Date:

January 11, 2002

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)


Exam. Init.	Ref. Des.	Citation
	C3	Bayer and Wilchek, "Avidin- and Streptavidin-containing probes," <i>Methods in Enzymology</i> , 184:174-187, 1990.
	C4	Bookman, "Biologic therapies for gynecologic cancer," <i>Curr. Opin. Oncol.</i> , 7(5):478-484, 1995.
	C5	Chinol <i>et al.</i> , "Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity," <i>Brit. J. Cancer</i> , 78(2):189-197, 1998.
	C6	Coleman, "Chemical sensitizers and protectors," <i>Int. J. Radiation Onc. Biol. Phys.</i> , 42(4):781-783, 1998.
	C7	Corely <i>et al.</i> , "Binding of biotinylated-liposomes to streptavidin is influenced by liposome composition," <i>Biochim. Biophys. Acta</i> , 1195:149-156, 1994.
	C8	Cox <i>et al.</i> , "Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer," <i>Ann. Surg.</i> , 227(5):645-653, 1998.
	C9	Daemen <i>et al.</i> , "Liposomes and virosomes as immunoadjuvant and antigen-carrier systems in vaccine formulations," In: <i>Medical Applications of Liposomes</i> , Lasic and Papahadjopoulos (eds), Elsevier Science B.V., 117-143, 1998.
	C10	DeCicco <i>et al.</i> , "Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer," <i>J. Nucl. Med.</i> , 39(12):2080-2084, 1998.
	C11	DeFrees <i>et al.</i> , "Sialyl Lewis X liposomes as a multivalent ligand and inhibitor of E-selectin mediated cellular adhesion," <i>J. Am. Chem. Soc.</i> , 118:6101-6104, 1996.
	C12	DeVita <i>et al.</i> , "Principles of cancer management: cancer genetics," In: <i>Cancer: Principles and Practice of Oncology</i> , 5 th ed., J.B. Lippincott Co., Philadelphia, PA, Chapter 14: 285-293, 1997.
	C13	Gabizon <i>et al.</i> , "Targeting folate receptor with folate linked to extremities of Poly(ethylene glycol)-grafted liposomes: in vitro studies," <i>Bioconjugate Chem.</i> , 10:289-298, 1999.
	C14	Goodman <i>et al.</i> , <i>The Pharmacological Basis of Therapeutics</i> , Gilman <i>et al.</i> (eds), Macmillan Publishing Co., New York, 1985.
	C15	Goodwin <i>et al.</i> , "Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens," <i>J. Nucl. Med.</i> , 29(2):226-234, 1988.

25135737.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



TECH CENTER 1600/2900

JUN 25 2002

RECEIVED

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSK:343US

10/044,650

List of Patents and Publications for Applicant's

Applicant

Beth A. Goins

William T. Phillips

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

January 11, 2002

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C16	Gregoriadis <i>et al.</i> , "DNA vaccination: a role for liposomes," In: <i>Medical Applications of Liposomes</i> , Lasic and Papahadjopoulos (eds), Elsevier Science B.V., 61-73, 1998.
	C17	Gregoriadis, "Liposomes as immunological adjuvants," <i>The Theory and Practical Application of Adjuvants</i> , 7:145-169, 1995.
	C18	Griffiths <i>et al.</i> , "Direct radiolabeling of monoclonal antibodies with generator-produced Rhenium-188 for radioimmunotherapy: labeling and animal biodistribution studies," <i>Cancer Res.</i> , 51(17):4594-4602, 1991.
	C19	Hader <i>et al.</i> , "Sentinel lymph node biopsy using lymphoscintigraphy," <i>AORN J.</i> , 68:572-588, 1998.
	C20	Heeremans <i>et al.</i> , "Fibrin binding of plasminogen coated liposomes in vitro," <i>Thromb Haemost.</i> , 75(1):134-139, 1996.
	C21	Hermanson, "Preparation of antibody—liposome conjugates," In: <i>Bioconjugate Techniques</i> , Academic Press, San Diego, CA, p.552-553, 1996.
	C22	Hermanson, "Use of glycolipids and lectins to effect specific conjugations," In: <i>Bioconjugate Techniques</i> , Academic Press, San Diego, CA, p.548-549, 1996.
	C23	Hirnle, "Liposomes for drug targeting in the lymphatic system," <i>Hybridoma</i> , 16(1):127-132, 1997.
	C24	Hnatowich <i>et al.</i> , "Improved tumor localization with (strept)avidin and labeled biotin as a substitute for antibody," <i>Nucl. Med. Biol.</i> , 20:189-195, 1993.
	C25	Hnatowich <i>et al.</i> , "Investigations of avidin and biotin for imaging applications," <i>J. Nucl. Med.</i> , 28(8):1294-1302, 1987.
	C26	Hope <i>et al.</i> , "Production of large unilamellar vesicles by a rapid extrusion procedures. Characterization of size distribution, trapped volume and ability to maintain a membrane potential," <i>Biochim. Et Biophys. Acta</i> , 812:55-65, 1985.
	C27	Jeong <i>et al.</i> , "Avidin-biotin system for targeting metastases: basic aspects," In: <i>Handbook of Targeted Delivery of Imaging Agents</i> , Chapter 18:305-319, CRC Press, 1995.
	C28	Johnsson <i>et al.</i> , "Optimization of drug loading procedures and characterization of liposomal formulations of two novel agents intended for boron neutron capture therapy (BNCT)," <i>J. Liposome Res.</i> , 9(1):53-79, 1999.

25135737.1

EXAMINER:

DATE CONSIDERED:


EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

RECEIVED

JUN 25 2002

TECH CENTER 1600/2900



Form PTO-1449 (modified)

Atty. Docket No.

UTSK:343US

Serial No.

10/044,650

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Beth A. G ins

William T. Phillips

Filing Date:

January 11, 2002

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C29	Kalofonos <i>et al.</i> "Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication," <i>J. Nucl. Med.</i> , 31(11):1791-1796, 1990.
	C30	Kang and Pardridge, "Use of neutral avidin improves pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal antibody conjugate," <i>J. Pharm. Experimental Therapeutics</i> , 269:344-350, 1994.
	C31	Klibanov <i>et al.</i> , "Blood clearance of radiolabeled antibody: enhancement by lactosamination and treatment with biotin-avidin or anti-mouse IgG antibodies," <i>J. Nucl. Med.</i> , 29(12):1951-1956, 1988.
	C32	Klibanov, "Targeted delivery of gas-filled microspheres, contrast agents for ultrasound imaging," <i>Adv. Drug Delivery Rev.</i> , 37:139-157, 1999.
	C33	Kohno <i>et al.</i> , "Drug delivery systems for infection: liposome-incorporating antimicrobial drugs," <i>J. Infect Chemother.</i> , 4:159-173, 1998.
	C34	Komura <i>et al.</i> , "Thermal neutron capture therapy of malignant melanoma using 10B-monoclonal antibodies: in vitro and in vivo analysis," <i>Melanoma Res.</i> , 1(5-6):397-403, 1991.
	C35	Kotz, "Advancing medical care: the role of nuclear medicine in radioguided surgery," <i>J. Nucl. Med.</i> , 39(12):13N-21N, 1998.
	C36	Krag <i>et al.</i> , "Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe," <i>Surg. Oncol.</i> , 2:335-339, 1993.
	C37	Krag <i>et al.</i> , "The sentinel node in breast cancer—a multicenter validation study," <i>N. Engl. J. Med.</i> , 339(14):941-946, 1998.
	C38	Krause, "Delivery of diagnostic agents in computed tomography," <i>Adv. Drug Delivery Rev.</i> , 37:159-173, 1999.
	C39	Kung <i>et al.</i> , "Antibody-bearing liposomes improve agglutination of latex particles used in clinical diagnostic assays," <i>Biochim Biophys. Acta</i> , 839:105-109, 1985.
	C40	Lasic and Pearlman, "Liposomes and lipidic particles in gene therapy," In: <i>Vesicles</i> , Marcel Dekker, New York, 477-489, 1996.
	C41	Leserman <i>et al.</i> , "Ligand targeting of liposomes," In: <i>Liposomes from Biophysics to Therapeutics</i> , Ostro (ed), Marcel Dekker, New York, p. 157-194, 1987.
	C42	Lindblad, "Aluminium adjuvants," <i>Theory Prac. Appl. Adjuvants</i> , 2:21-35, 1995.

25135737.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSK:343US

10/044,650

List of Patents and Publications for Applicant's

Applicant

Beth A. Goins

William T. Phillips

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

January 11, 2002

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C43	Litzinger and Huang, "Amphipathic poly(ethylene glycol) 5000-stabilized dioleoylphosphatidylethanolamine liposomes accumulate in spleen," <i>Biochim Biophys. Acta</i> , 1127(3):249-254, 1992.
	C44	Magnani <i>et al.</i> , "Quantitative comparison of direct antibody labeling and tumor pretargeting in Uveal melanoma," <i>J. Nucl. Med.</i> , 37(6):967-971, 1996.
	C45	Mayer <i>et al.</i> , "Vesicles of variable sizes produced by a rapid extrusion procedure," <i>Biochim Biophys Acta</i> , 858:161-168, 1986.
	C46	Mayhew <i>et al.</i> , "High-pressure continuous-flow system for drug entrapment in liposomes," <i>Methods Enzym.</i> , 149:64-77, 1987.
	C47	Meares <i>et al.</i> , "Macrocyclic chelates of radiometals for diagnosis and therapy," <i>Br. J. Cancer</i> , 62 (Suppl 10):21-26, 1990.
	C48	Moghimi and Rajabi-Siahboomi, "Advanced colloid-based systems for efficient delivery of drugs and diagnostic agents to the lymphatic tissues," <i>Prog. Biophys. Molec. Biol.</i> , 65:221-249, 1996.
	C49	Moghimi <i>et al.</i> , "Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes," <i>FESB Letters</i> , 344:25-30, 1994.
	C50	Morton <i>et al.</i> , "Management of early-stage melanoma by intraoperative lymphatic mapping and selective lymphadenectomy," <i>Surg. Oncol. Clin. N. Am.</i> , 1:247-259, 1992.
	C51	Morton <i>et al.</i> , "Technical details of intraoperative lymphatic mapping for early stage melanoma," <i>Arch. Surg.</i> , 127(4):392-399, 1992.
	C52	New, "Preparation of liposomes," In: <i>Liposomes: A Practical Approach</i> , New (ed), Oxford University Press, NY 33-104, 1990.
	C53	Oehr <i>et al.</i> , "Streptavidin and biotin as potential tumor imaging agents," <i>J. Nucl. Med.</i> , 29:728-729, 1988.
	C54	Ogihara-Umeda <i>et al.</i> , "Rapid diagnostic imaging of cancer using radiolabeled liposomes," <i>Cancer Detection and Prevention</i> , 21(6):490-496, 1997.
	C55	Okuhata, "Delivery of diagnostic agents for magnetic resonance imaging," <i>Advanced Drug Delivery</i> , 37:121-137, 1999.

25135737.1


EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

RECEIVED

JUN 25 2002



Form PTO-1449 (modified)	Atty. Docket No. UTSK:343US	Serial No. 10/044,650
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Beth A. Goins William T. Phillips	
	Filing Date: January 11, 2002	Group: 1645
	U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C56	Oussoren and Storm, "Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: III. Influence of surface modification with Poly(ethyleneglycol)," <i>Pharm Res.</i> , 14(10):1479-1484, 1997.
	C57	Oussoren <i>et al.</i> , "Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose," <i>Biochim. Biophys. Acta</i> , 1328:261-272, 1997.
	C58	Paganelli <i>et al.</i> , "Monoclonal antibody pretargeting techniques for tumour localization: the avidin-biotin system," <i>Nucl. Med. Commun.</i> , 12(3):211-234, 1991.
	C59	Paganelli <i>et al.</i> , "Potential of the avidin-biotin system for diagnostic application," In: <i>Handbook of Targeted Delivery of Imaging Agents</i> , Chap. 17, CRC Press, 289-303, 1995.
	C60	Paganelli <i>et al.</i> , "The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapy," <i>Eur. J. Nucl. Med.</i> , 24(3):350-351, 1997.
	C61	Paganelli <i>et al.</i> , "Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients," <i>Cancer Res.</i> , 51(21):5960-5966, 1991.
	C62	Paganelli <i>et al.</i> , "Two-step tumour targeting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin," <i>Eur. J. Nucl. Med.</i> , 19(5):322-329, 1992.
	C63	Papisov <i>et al.</i> , "Drug delivery to lymphatic tissue," <i>Crit Rev. Ther. Drug Carrier Syst.</i> , 13(1&2):57-84, 1996.
	C64	Phillips and Goins, "Targeted delivery of imaging agents by liposomes," In: <i>Handbook of Targeted Delivery of Imaging Agents</i> , Chap. 10, CRC Press, 149-173, 1995.
	C65	Phillips <i>et al.</i> , "Novel method of greatly enhanced delivery of anti-cancer agents to lymph nodes," <i>9th Annual Symposium on Cancer Research in San Antonio</i> , Abstract #23, July 16, 1999.
	C66	Pykett, "NMR imaging in medicine," <i>Sci Am.</i> , 246(5):78-88, 1982.
	C67	Rao <i>et al.</i> , "A trivalent system from vancomycin-D-Ala-D-Ala with higher affinity than avidin-biotin," <i>Science</i> , 280(5364):708-711, 1999.

25135737.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial N.

UTSK:343US

10/044,650

List of Patents and Publications for Applicant's

Applicant

Beth A. G ins

William T. Phillips

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

January 11, 2002

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C68	Rawls, "Bringing Boron to bear on cancer. Chemists near goal of delivering a billion ¹⁰ B atoms selectively to cells to target them for destruction via neutron capture therapy," <i>C&EN</i> , 26-29, March 22, 1999.
	C69	Reintgen, "The role of lymphoscintigraphy in lymphatic mapping for melanoma and breast cancer," <i>J. Nucl. Med.</i> , 39(12):22N-36N, 1998.
	C70	Runge <i>et al.</i> , "Paramagnetic agents for contrast-enhanced NMR imaging: a review," <i>Am. J. Roentgeno.</i> , 141(6):1209-1215, 1983.
	C71	Schechter <i>et al.</i> , "Indirect immunotargeting of CIS-PT to human epidermoid carcinoma KB using the avidin-biotin system," <i>Int. J. Cancer</i> , 48:167-172, 1991.
	C72	Schuber, "Chemistry of ligand-coupling to liposomes," In: <i>Liposomes as Tools in Basic Research and Industry</i> , Philippot and Schuber (eds.), CRC Press, Boca Raton, 21-39, 1995.
	C73	Sigma Catalog, Alphabetical list of compounds, 149-150, 1999.
	C74	Sinitsyn <i>et al.</i> , "Rapid blood clearance of biotinylated IgG after infusion of avidin," <i>J. Nucl. Med.</i> , 30(1):66-69, 1989.
	C75	Sinkula and Yalkowsky, "Rationale for design of biologically reversible drug derivatives: prodrugs," <i>J. Pharm. Sci.</i> , 64:181-210, 1975.
	C76	Stickney <i>et al.</i> , "Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma," <i>Cancer Res.</i> , 51(24):6650-6655, 1991.
	C77	Strand and Bergqvist, "Radiolabeled colloids and macromolecules in the lymphatic system," <i>Crit. Rev. Ther. Drug Carrier Syst.</i> , 6(3):211-237, 1989.
	C78	Swinyard, "Analgesics and antipyretics," <i>Remington's Pharmaceutical Sciences</i> , 15 th ed., pp. 1035-1038 and 1570-1580.
	C79	Tanabe and Reintgen, "The role of sentinel lymph node mapping for melanoma," <i>Adv. Surg.</i> , 31:79-103, 1998.
	C80	Terskikh <i>et al.</i> , "Peptabody: a new type of high avidity binding protein," <i>Proc. Natl. Acad. Sci. USA</i> , 94:1663-1668, 1997.
	C81	Tiong <i>et al.</i> , "Comparison of conventional adjuvants and "adjuvant-free" monoclonal antibody targeting for stimulating antibody responses against a conjugate of luteinizing hormone releasing hormone and avidin," <i>Vaccine</i> , 11(4):425-430, 1993.

25135737.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSK:343US

10/044,650

List of Patents and Publications for Applicant's

Applicant

Beth A. Goins

William T. Phillips

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

January 11, 2002

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C82	Tiourina <i>et al.</i> , "Evaluation of surgical gamma probes for radioguided sentinel node localisation," <i>Eur. J. Nucl. Med.</i> , 25(9):1224-1231, 1998.
	C83	Van der Veen <i>et al.</i> , "Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy," <i>Br. J. Surg.</i> , 81(12):1769-1770, 1994.
	C84	Veronesi <i>et al.</i> , "Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes," <i>Lancet</i> , 349(9069):1864-1867, 1997.
	C85	Weiss <i>et al.</i> , <i>Lymphatic System Metastasis</i> , Hall, Boston, 1980.
	C86	Wilbur <i>et al.</i> , "Biotin reagents for antibody pretargeting. 3. Synthesis, radioiodination, and evaluation of biotinylated starburst dendrimers," <i>Bioconjugate Chem.</i> , 9:813-825, 1998.
	C87	Wolf, "Specific imaging agents for lymph nodes," In: <i>Handbook of Targeted Delivery of Imaging Agents</i> , Chap. 21, 365-384, CRC Press, 1995.
	C88	Woodle and Leserman, "Liposomal antisense oligonucleotide therapeutics," <i>Lasic and Papahadjopoulos (eds.) Medical Applications of Liposomes</i> , Elsevier Science B.V., 429-449, 1998.
	C89	Yoffrey and Courtice, <i>Lymphatics, lymph and the lymphomyeloid complex</i> , Academic Press, London, 1970.
	C90	Yuan <i>et al.</i> , "Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies," <i>Cancer Res.</i> , 51(12):3119-3130, 1991.

25135737.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)